Acadia Pharmaceuticals ACAD Current ratio

Current ratio at other companies

BiogenBIIB

1.9×-0.6×

Neurocrine BiosciencesNBIX

2.9×-0.2×

MapLight Therapeutics, Inc.MPLT

22.9×—

Taysha Gene Therapies, Inc.TSHA

14×+8.7×

Zevra Therapeutics, Inc.ZVRA

5.2×-2.7×

LBR

LB Pharmaceuticals IncLBRX

35.7×—

FAQ

What is Acadia Pharmaceuticals's current ratio?

Acadia Pharmaceuticals (ACAD) reported current ratio of 3.4× in Q2 2026.

How has Acadia Pharmaceuticals's current ratio changed year-over-year?

Acadia Pharmaceuticals's current ratio increased by 16.4% year-over-year, from 2.9× to 3.4×.

What is the long-term trend for Acadia Pharmaceuticals's current ratio?

Over 5 years (2020 to 2025), Acadia Pharmaceuticals's current ratio has grown at a -10.8% compound annual growth rate (CAGR), from 6.8× to 3.8×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.